WELL at $3.92: Cheap After the Sell-Off, or Still a Growth Trap?

WELL at 3.92: the stock looks cheap only if the earnings base holds

At the current share price of 3.920, WELL looks cheap mainly through near-term earnings, not because valuation alone solves the story. After the recent sell-off, the market is asking a narrower question: is profitability durable?

Record 2025 revenue of $1.40 billion and record Adjusted EBITDA of $203.7 million give supporters a real baseline. But after Q1 revenue up 25%, management only reaffirmed annual guidance rather than lifting it. The debate is no longer whether WELL can grow. It is whether investors can trust the consistency and quality of those earnings.

My view: WELL is more interesting here than at the top, but it is still an earnings-trust trade. If the next few quarters show a cleaner profit path, the multiple can expand. If not, the stock can stay cheap even with solid revenue growth.

The real split is between reported strength and core operating durability

The market is divided between two readings of the same data.

• Bulls see a healthcare platform that scaled quickly, started 2026 with strong growth, and still has a core Canadian business that is compounding.
• Bears see reported margins that can look cheap only if the market stops trusting how much of the improvement came from one-time items and acquisition integration.

That makes the current setup more nuanced than a simple bargain-stock thesis.

Normalized 2025 numbers were strong, but more modest than headline results

The clearest example is the gap between reported and normalized 2025 figures. WELL reported record revenue of $1.40 billion and record Adjusted EBITDA of $203.7 million. But excluding Circle Medical and CRH-related one-time events, normalized revenue would have reached $1.35 billion in 2025 and Adjusted EBITDA would have been $148.6 million.

That gap matters. It shows part of the reported leap was not pure core operating leverage. It also explains why investors are scrutinizing the quality of the earnings base rather than just the headline growth rate.

Q1-26 validated the plan, but it did not clearly re-accelerate it

Quarterly revenue of $368.3 million, up 25%, was strong. Adjusted EBITDA of $43.1 million also showed the business was still generating healthy profitability. But management only reaffirmed its annual guidance.

That is encouraging, but it is not the same as a fresh upside beat. For bulls, it is proof the plan still works. For bears, it suggests WELL still needs stable execution and favorable timing to keep the narrative intact.

Canadian Patient Services remains the cleanest operating signal

The best window into the core business is Canadian Patient Services. In 2025, that segment delivered revenue increased 39% and Adjusted EBITDA increased 43%. In Q1-26, Canadian Patient Services revenues increased by 30% to $130.3 million and Adjusted EBITDA increased by 28% to $17.0 million.

That is the cleanest evidence that a core part of the business is still growing organically and expanding margins.

Has WELL fallen far enough? Only if trust in earnings rebuilds

After the move to 3.920, the key question is not whether the stock looks cheap on paper. It is whether management can show a more repeatable earnings path over the next few quarters.

The opportunity is real: WELL still has growth, a profitable core segment, and a lower share price than it held during its stronger momentum phase. The risk is equally clear: if reported margins remain too sensitive to one-time effects and acquisitions, the market may keep treating WELL as a growth stock with execution overhang rather than a simpler compounding story.

So yes, it may have fallen far enough for selective buyers. But the better setup is to watch whether proof starts to catch up with the narrative.